Provided by Tiger Trade Technology Pte. Ltd.

Can Fite Biofarma

2.33
+0.17007.87%
Post-market: 2.330.00000.00%19:54 EDT
Volume:154.99K
Turnover:354.13K
Market Cap:4.99M
PE:-0.50
High:2.37
Open:2.17
Low:2.16
Close:2.16
52wk High:13.40
52wk Low:2.16
Shares:2.14M
Float Shares:2.14M
Volume Ratio:0.95
T/O Rate:7.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6460
EPS(LYR):-1,791.0249
ROE:-211.37%
ROA:-77.12%
PB:1.03
PE(LYR):0.00

Loading ...

Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY

Benzinga Earnings
·
Sep 08

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Dow Jones
·
Sep 08

Top Midday Decliners

MT Newswires Live
·
Sep 03

Can-Fite BioPharma Announces $4 Million Warrant Exercise

MT Newswires Live
·
Sep 02

Can-Fite BioPharma Files $100 Million Shelf

MT Newswires Live
·
Aug 29

Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson

TIPRANKS
·
Jul 14

Can-Fite BioPharma Completes Enrollment in Phase 3 Study of Potential Plaque Psoriasis Treatment

MT Newswires Live
·
Jul 06

Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

TIPRANKS
·
Jul 06

Can-fite Biopharma Price Target Raised to $8.00/share from $5.00 by HC Wainwright & Co.

Dow Jones
·
Jul 02

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

TIPRANKS
·
Jul 02

Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes

MT Newswires Live
·
Jul 02

Can-Fite Secures Japanese Patent for Namodenoson's Anti-Obesity Tech; Shares Up Pre-Bell

MT Newswires Live
·
Jun 26

Can-Fite Biopharma Raised to Buy From Hold by D. Boral Capital

Dow Jones
·
May 14

Can-Fite Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 12

Can-Fite BioPharma completes enrollment in Piclidenoson study

TIPRANKS
·
Mar 30

Press Release: Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Dow Jones
·
Mar 26

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

TIPRANKS
·
Mar 17